Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia

Judith Karp, Tatiana I. Vener, Mitch Raponi, Ellen K. Ritchie, B Douglas Smith, Steven D. Gore, Lawrence E. Morris, Eric J. Feldman, Jacqueline M. Greer, Sami Malek, Hetty E. Carraway, Valerie Ironside, Steven Galkin, Mark J Levis, Michael A. McDevitt, Gail R. Roboz, Christopher Gocke, Carlo Derecho, John Palma, Yixin WangScott H. Kaufmann, John J. Wright, Elizabeth Garret-Mayer

Research output: Contribution to journalArticle

Abstract

Tipifarnib (T) exhibits modest activity in elderly adults with newly diagnosed acute myelogenous leukemia (AML). Based on preclinical synergy, a phase 1 trial of T plus etoposide (E) yielded 25% complete remission (CR). We selected 2 comparable dose levels for a randomized phase 2 trial in 84 adults (age range, 70-90 years; median, 76 years) who were not candidates for conventional chemotherapy. ArmA(T 600 mg twice a day x 14 days, E 100 mg days 1-3 and 8-10) and arm B (T 400 mg twice a day x 14 days, E 200 mg days 1-3 and 8-10) yielded similar CR, but arm B had greater toxicity. Total CR was 25%, day 30 death rate 7%.A 2-gene signature of high RASGRP1 and low aprataxin (APTX) expression previously predicted for T response. Assays using blasts from a subset of 40 patients treated with T plus E on this study showed that AMLs with a RASGRP1/APTX ratio of more than 5.2 had a 78% CR rate and negative predictive value 87%. This ratio did not correlate with outcome in 41 patients treated with conventional chemotherapies. The next T-based clinical trials will test the ability of the 2-gene signature to enrich for T responders prospectively. This study is registered at www.clinicaltrials. gov as #NCT00602771.

Original languageEnglish (US)
Pages (from-to)55-63
Number of pages9
JournalBlood
Volume119
Issue number1
DOIs
StatePublished - Jan 5 2012

Fingerprint

tipifarnib
Chemotherapy
Pharmacogenetics
Etoposide
Acute Myeloid Leukemia
Genes
Clinical Trials
Drug Therapy
Toxicity
Assays
Mortality

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia. / Karp, Judith; Vener, Tatiana I.; Raponi, Mitch; Ritchie, Ellen K.; Smith, B Douglas; Gore, Steven D.; Morris, Lawrence E.; Feldman, Eric J.; Greer, Jacqueline M.; Malek, Sami; Carraway, Hetty E.; Ironside, Valerie; Galkin, Steven; Levis, Mark J; McDevitt, Michael A.; Roboz, Gail R.; Gocke, Christopher; Derecho, Carlo; Palma, John; Wang, Yixin; Kaufmann, Scott H.; Wright, John J.; Garret-Mayer, Elizabeth.

In: Blood, Vol. 119, No. 1, 05.01.2012, p. 55-63.

Research output: Contribution to journalArticle

Karp, J, Vener, TI, Raponi, M, Ritchie, EK, Smith, BD, Gore, SD, Morris, LE, Feldman, EJ, Greer, JM, Malek, S, Carraway, HE, Ironside, V, Galkin, S, Levis, MJ, McDevitt, MA, Roboz, GR, Gocke, C, Derecho, C, Palma, J, Wang, Y, Kaufmann, SH, Wright, JJ & Garret-Mayer, E 2012, 'Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia', Blood, vol. 119, no. 1, pp. 55-63. https://doi.org/10.1182/blood-2011-08-370825
Karp, Judith ; Vener, Tatiana I. ; Raponi, Mitch ; Ritchie, Ellen K. ; Smith, B Douglas ; Gore, Steven D. ; Morris, Lawrence E. ; Feldman, Eric J. ; Greer, Jacqueline M. ; Malek, Sami ; Carraway, Hetty E. ; Ironside, Valerie ; Galkin, Steven ; Levis, Mark J ; McDevitt, Michael A. ; Roboz, Gail R. ; Gocke, Christopher ; Derecho, Carlo ; Palma, John ; Wang, Yixin ; Kaufmann, Scott H. ; Wright, John J. ; Garret-Mayer, Elizabeth. / Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia. In: Blood. 2012 ; Vol. 119, No. 1. pp. 55-63.
@article{b8ce38864cf3466699a002507dd105f1,
title = "Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia",
abstract = "Tipifarnib (T) exhibits modest activity in elderly adults with newly diagnosed acute myelogenous leukemia (AML). Based on preclinical synergy, a phase 1 trial of T plus etoposide (E) yielded 25{\%} complete remission (CR). We selected 2 comparable dose levels for a randomized phase 2 trial in 84 adults (age range, 70-90 years; median, 76 years) who were not candidates for conventional chemotherapy. ArmA(T 600 mg twice a day x 14 days, E 100 mg days 1-3 and 8-10) and arm B (T 400 mg twice a day x 14 days, E 200 mg days 1-3 and 8-10) yielded similar CR, but arm B had greater toxicity. Total CR was 25{\%}, day 30 death rate 7{\%}.A 2-gene signature of high RASGRP1 and low aprataxin (APTX) expression previously predicted for T response. Assays using blasts from a subset of 40 patients treated with T plus E on this study showed that AMLs with a RASGRP1/APTX ratio of more than 5.2 had a 78{\%} CR rate and negative predictive value 87{\%}. This ratio did not correlate with outcome in 41 patients treated with conventional chemotherapies. The next T-based clinical trials will test the ability of the 2-gene signature to enrich for T responders prospectively. This study is registered at www.clinicaltrials. gov as #NCT00602771.",
author = "Judith Karp and Vener, {Tatiana I.} and Mitch Raponi and Ritchie, {Ellen K.} and Smith, {B Douglas} and Gore, {Steven D.} and Morris, {Lawrence E.} and Feldman, {Eric J.} and Greer, {Jacqueline M.} and Sami Malek and Carraway, {Hetty E.} and Valerie Ironside and Steven Galkin and Levis, {Mark J} and McDevitt, {Michael A.} and Roboz, {Gail R.} and Christopher Gocke and Carlo Derecho and John Palma and Yixin Wang and Kaufmann, {Scott H.} and Wright, {John J.} and Elizabeth Garret-Mayer",
year = "2012",
month = "1",
day = "5",
doi = "10.1182/blood-2011-08-370825",
language = "English (US)",
volume = "119",
pages = "55--63",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "1",

}

TY - JOUR

T1 - Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia

AU - Karp, Judith

AU - Vener, Tatiana I.

AU - Raponi, Mitch

AU - Ritchie, Ellen K.

AU - Smith, B Douglas

AU - Gore, Steven D.

AU - Morris, Lawrence E.

AU - Feldman, Eric J.

AU - Greer, Jacqueline M.

AU - Malek, Sami

AU - Carraway, Hetty E.

AU - Ironside, Valerie

AU - Galkin, Steven

AU - Levis, Mark J

AU - McDevitt, Michael A.

AU - Roboz, Gail R.

AU - Gocke, Christopher

AU - Derecho, Carlo

AU - Palma, John

AU - Wang, Yixin

AU - Kaufmann, Scott H.

AU - Wright, John J.

AU - Garret-Mayer, Elizabeth

PY - 2012/1/5

Y1 - 2012/1/5

N2 - Tipifarnib (T) exhibits modest activity in elderly adults with newly diagnosed acute myelogenous leukemia (AML). Based on preclinical synergy, a phase 1 trial of T plus etoposide (E) yielded 25% complete remission (CR). We selected 2 comparable dose levels for a randomized phase 2 trial in 84 adults (age range, 70-90 years; median, 76 years) who were not candidates for conventional chemotherapy. ArmA(T 600 mg twice a day x 14 days, E 100 mg days 1-3 and 8-10) and arm B (T 400 mg twice a day x 14 days, E 200 mg days 1-3 and 8-10) yielded similar CR, but arm B had greater toxicity. Total CR was 25%, day 30 death rate 7%.A 2-gene signature of high RASGRP1 and low aprataxin (APTX) expression previously predicted for T response. Assays using blasts from a subset of 40 patients treated with T plus E on this study showed that AMLs with a RASGRP1/APTX ratio of more than 5.2 had a 78% CR rate and negative predictive value 87%. This ratio did not correlate with outcome in 41 patients treated with conventional chemotherapies. The next T-based clinical trials will test the ability of the 2-gene signature to enrich for T responders prospectively. This study is registered at www.clinicaltrials. gov as #NCT00602771.

AB - Tipifarnib (T) exhibits modest activity in elderly adults with newly diagnosed acute myelogenous leukemia (AML). Based on preclinical synergy, a phase 1 trial of T plus etoposide (E) yielded 25% complete remission (CR). We selected 2 comparable dose levels for a randomized phase 2 trial in 84 adults (age range, 70-90 years; median, 76 years) who were not candidates for conventional chemotherapy. ArmA(T 600 mg twice a day x 14 days, E 100 mg days 1-3 and 8-10) and arm B (T 400 mg twice a day x 14 days, E 200 mg days 1-3 and 8-10) yielded similar CR, but arm B had greater toxicity. Total CR was 25%, day 30 death rate 7%.A 2-gene signature of high RASGRP1 and low aprataxin (APTX) expression previously predicted for T response. Assays using blasts from a subset of 40 patients treated with T plus E on this study showed that AMLs with a RASGRP1/APTX ratio of more than 5.2 had a 78% CR rate and negative predictive value 87%. This ratio did not correlate with outcome in 41 patients treated with conventional chemotherapies. The next T-based clinical trials will test the ability of the 2-gene signature to enrich for T responders prospectively. This study is registered at www.clinicaltrials. gov as #NCT00602771.

UR - http://www.scopus.com/inward/record.url?scp=84862907863&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862907863&partnerID=8YFLogxK

U2 - 10.1182/blood-2011-08-370825

DO - 10.1182/blood-2011-08-370825

M3 - Article

C2 - 22001391

AN - SCOPUS:84862907863

VL - 119

SP - 55

EP - 63

JO - Blood

JF - Blood

SN - 0006-4971

IS - 1

ER -